Key result
Trastuzumab plus pertuzumab yielded an 18% objective response rate and left ventricular systolic dysfunction in 6 of 11 patients with trastuzumab-insensitive HER2-positive metastatic breast cancer.
Why the study?
Does the combination of trastuzumab and pertuzumab cause cardiac toxicity and provide efficacy in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer?
Population
11 patients with measurable HER2-positive metastatic breast cancer who had progressive disease on…
Design
Case_series
Authors
Loading...
Supports dual HER2 blockade after trastuzumab progression; leaves open randomized confirmation of clinical benefit.
Does the combination of trastuzumab and pertuzumab cause cardiac toxicity and provide efficacy in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer?
The combination of trastuzumab and pertuzumab in trastuzumab-pretreated HER2-positive metastatic breast cancer provides modest clinical benefit but is associated with frequent, albeit mostly asymptomatic, left ventricular systolic dysfunction.
Portera et al. (2008) studied HER2-positive metastatic breast cancer (n=11). Trastuzumab plus pertuzumab was evaluated on Objective response rate. Trastuzumab plus pertuzumab yielded an 18% objective response rate and left ventricular systolic dysfunction in 6 of 11 patients with trastuzumab-insensitive HER2-positive metastatic breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: